Fermenta Biotech Ltd Q1 FY22 Earnings Call Analysis
Revenue, margin, capex, fundraise and order book outlook from management commentary.
Management growth scorecard
Revenue
Category 3
Margin
Category 3
Fundraise
N/A
Order
N/A
Capex
Yes
1 of 3 growth signals are positive — mixed outlook.
Full analysisRevenue guidance
Category 3- Human nutrition (Vitamin D3) volumes grew ~70% YoY in Q1 FY22, driven partly by COVID-related demand and increased awareness of immunity benefits.
- Management expects continued strong double-digit growth in human nutrition volumes, though not at the unsustainable 70% level.
- Animal nutrition volumes declined ~64% YoY due to pandemic and African swine flu impacts but are expected to recover as global economies reopen.
- The company anticipates stable or improving prices for human Vitamin D3, with supply capacity expected to be fully utilized after a 20% expansion within the current financial year.
- Fermenta USA acquisition provides access to a larger dietary and nutrition market, with plans to expand manufacturing and product basket, including premixes, over the next 12 months.
- Long-term revenue CAGR target is approximately 15% with an EBITDA margin around 25%.
See what Fermenta Biotech Ltd management said on margin guidance — free account, 30 seconds.
Fundraise plans
- The transcript does not mention any current or planned fundraising through debt or equity.
- No discussions or statements about raising capital via equity or debt were made during the Q1FY22 results conference call.
- The focus was on capacity expansion through internal funds and existing resources, such as greenfield projects in Saykha.
- Management discussed evaluating CapEx requirements but did not reference external fundraising.
- Overall, no specific information about new fundraising plans is provided in this transcript.
See what Fermenta Biotech Ltd management said on order book — free account, 30 seconds.
Capex plans
Yes- Fermenta Biotech has recently completed backward integration for cholesterol, with a substantial property, plant, and equipment increase of about ₹60-65 crores in FY21.
- Around ₹35 crores in Capital Work-in-Progress (CWIP) relates to capacity expansion capitalized in Q1 FY22.
- A 20% capacity expansion specifically for human vitamin D3 is completed and expected to be fully utilized within the current financial year.
- Further incremental capacity expansions at the current Dahej plant are not possible due to space constraints.
- New greenfield projects are planned at Saykha (10 acres of land and environmental permissions in place).
- The company is evaluating product baskets for the Saykha project, including vitamin D3 expansion.
- The total capex for the greenfield project will depend on the product mix.
- These projects aim to reduce dependence on vendors, strengthen security, stability, and cost-effectiveness.
Track Fermenta Biotech Ltd — get its next earnings analysis in your feed
Margin guidance
Category 3- Fermenta Biotech targets a long-term CAGR revenue growth of around 15% over the next five years.
- The company aims to maintain an EBITDA margin of approximately 25% in the long term.
- For Q1FY22, revenue increased by ~16% year-on-year and EBITDA grew by ~15% year-on-year, indicating positive momentum.
- Net profit after tax (PAT) for Q1FY22 was ₹11 crore, representing a 53% increase quarter-on-quarter, though down 17% year-on-year due to tax adjustments.
- Capacity expansion (notably 20% increase in human vitamin D capacity) is expected to be fully utilized within the financial year, supporting future growth.
- Management remains optimistic about sustained double-digit volume growth in human nutrition vitamin D3, driven by increasing market demand post-COVID.
- The company refrains from giving specific forward-looking margin or ROE guidance but focuses on steady growth and profitability improvements.
Order book
How does Fermenta Biotech Ltd rank vs peers in Pharmaceuticals & Biotechnology?
Pro featureHow does Fermenta Biotech Ltd rank in Pharmaceuticals & Biotechnology?
Compare Fermenta Biotech Ltd against every Pharmaceuticals & Biotechnology company (Q1 FY22) on revenue, margins and earnings-call signals.
Continue your research
What Fermenta Biotech Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- IOL Chemicals (Q1 FY27)
Expansion plans supported by capex of INR 200-250 crores annually, with 60% towards expansion/new products and 40% towards efficiency improvements. Key concall…
- Innova Captab Ltd (Q1 FY27)
The company is confident of achieving 20%+ volume growth backed by steady ramp-up in Jammu and existing facilities. Key concall takeaways from Innova Captab…
- Glenmark Pharma. (Q1 FY27)
Chronic respiratory segment in India showing over 25% growth; oncology and cardiovascular segments also strong. Key concall takeaways from Glenmark…
- Strides Pharma Science Ltd (Q1 FY27)
markets continue to be broad-based growth drivers, with 17% YoY growth and expansion in B2B and B2C markets including Europe, UK, Nordics, Africa, LATAM, MENA…